TY - JOUR
T1 - Correction to
T2 - Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines (Vaccines, (2022), 10, 10, (1668), 10.3390/vaccines10101668)
AU - Murphy, Hannah L
AU - Ly, Hinh
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/8
Y1 - 2024/8
N2 - The authors would like to make the following corrections to this published paper [1]. In the original publication [1], there was a mistake in the first column of Table 1, published as “INO-4500 (MV backbone)”. The corrected notation for this should be “INO-4500 (DNA-based vaccine)”. There was an error in a sentence in the first paragraph of Section 4.1. Measles Virus Platform, published as “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC and is based on the Schwarz strain of the measles virus (MV) [94,95]”, which should be changed to the following version: “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC [94,95]”. The first sentence in the second paragraph of Section 4.1, “In addition to INO-4500, another vaccine candidate has been developed using the Schwarz MV vaccine platform, MV-LASV (V182-001, MeV-NP)”, should be removed. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
AB - The authors would like to make the following corrections to this published paper [1]. In the original publication [1], there was a mistake in the first column of Table 1, published as “INO-4500 (MV backbone)”. The corrected notation for this should be “INO-4500 (DNA-based vaccine)”. There was an error in a sentence in the first paragraph of Section 4.1. Measles Virus Platform, published as “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC and is based on the Schwarz strain of the measles virus (MV) [94,95]”, which should be changed to the following version: “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC [94,95]”. The first sentence in the second paragraph of Section 4.1, “In addition to INO-4500, another vaccine candidate has been developed using the Schwarz MV vaccine platform, MV-LASV (V182-001, MeV-NP)”, should be removed. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
UR - http://www.scopus.com/inward/record.url?scp=85202445309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202445309&partnerID=8YFLogxK
U2 - 10.3390/vaccines12080909
DO - 10.3390/vaccines12080909
M3 - Comment/debate
C2 - 39204075
AN - SCOPUS:85202445309
SN - 2076-393X
VL - 12
JO - Vaccines
JF - Vaccines
IS - 8
M1 - 909
ER -